Luxendo
Financials
Estimates*
EUR | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 |
---|---|---|---|---|---|---|---|
Revenues | - | - | - | 2.1m | 2.7m | 4.0m | 6.9m |
% growth | - | - | - | - | 28 % | 46 % | 72 % |
Profit | (<1m) | (2.0m) | (2.9m) | (2.2m) | (3.9m) | (2.7m) | <1m |
% profit margin | - | - | - | (103 %) | (141 %) | (69 %) | 1 % |
Date | Investors | Amount | Round |
---|---|---|---|
€6.0m | Series A | ||
* | €8.0m | Series A | |
N/A | Acquisition | ||
Total Funding | $15.4m |
Recent News about Luxendo
EditLuxendo, a Bruker company, specializes in advanced light sheet microscopy solutions designed for fast and high-resolution 3D imaging of live and optically cleared samples. The company serves a diverse range of clients, including research institutions, universities, and pharmaceutical companies, operating primarily in the bioimaging and life sciences markets. Luxendo's business model revolves around the development and sale of specialized microscopy equipment, such as the TruLive3D Imager and QuVi SPIM, which are optimized for multi-sample imaging and long-term fluorescence imaging, respectively. Additionally, Luxendo offers Lux DATA, a comprehensive data processing and storage solution tailored for handling the large volumes of data generated by their microscopes. Revenue is generated through the direct sale of these high-end microscopy systems and associated data solutions, as well as through service contracts and maintenance agreements.
Keywords: light sheet microscopy, 3D imaging, live specimens, cleared samples, bioimaging, fluorescence, data processing, research institutions, pharmaceutical companies, high-resolution.